FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD
Psychiatric Times
JULY 1, 2025
SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.
Let's personalize your content